Koers Matinas BioPharma Holdings Inc Other OTC
Aandelen
US5768101058
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 44,04 mln. 40,9 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -26 mln. -24,14 mln. | Nettowinst (verlies) 2025 * | -34 mln. -31,57 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-1,6
x | K/w-verhouding 2025 * |
-1,6
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,47% |
Recentste transcriptie over Matinas BioPharma Holdings Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jerome Jabbour
FOU | Founder | 50 | 01-05-13 |
Keith Kucinski
DFI | Director of Finance/CFO | 55 | 03-01-19 |
Hui Liu
CTO | Chief Tech/Sci/R&D Officer | 56 | 01-12-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Herbert Conrad
FOU | Founder | 91 | 01-05-13 |
Natasha Giordano
BRD | Director/Board Member | 62 | 14-09-20 |
Eric Ende
CHM | Chairman | 55 | 03-04-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+3,91% | 109 mld. | |
+10,87% | 105 mld. | |
+1,28% | 22,25 mld. | |
-13,14% | 22,09 mld. | |
-7,05% | 18,68 mld. | |
-38,36% | 17,58 mld. | |
-10,66% | 16,85 mld. | |
+3,75% | 13,76 mld. | |
+36,70% | 12,46 mld. |
- Beurs
- Aandelen
- Koers MTNB
- Koers